Literature DB >> 8605667

Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study.

J H Contois1, J R McNamara, C J Lammi-Keefe, P W Wilson, T Massov, E J Schaefer.   

Abstract

We evaluated a commercially available, standardized immunoturbidimetric assay for apolipoprotein (apo) B, the protein constituent of low-density lipoprotein (LDL), to establish reference ranges for men and women, and to determine the concentrations associated with increased risk of coronary heart disease (CHD). The between-run CV for assay of a normal-concentration control for this assay was 6.60%. The mean (+/-SD) apo B concentration was 1.03 +/- 0.24 g/L in 1880 men, significantly higher than the mean for 1944 women (0.96 +/- 0.26 g/L) participating in cycle 4 of the Framingham Offspring Study (P<0.001). An apo B value of 1.20 g/L corresponded roughly to the 75th percentile in men, similar to an LDL cholesterol concentration of 1.60 g/L, and subjects with concentrations greater than this were significantly more likely to have CHD than subjects with apo B concentrations less than 1.00 g/L, the approximate 50th percentile (P<0.05 in men and P<0.001 in women).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605667

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  22 in total

1.  Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.

Authors:  A D Sniderman; J Bergeron; J Frohlich
Journal:  CMAJ       Date:  2001-01-09       Impact factor: 8.262

2.  Impact of food matrix on isoflavone metabolism and cardiovascular biomarkers in adults with hypercholesterolemia.

Authors:  Jennifer Ahn-Jarvis; Steven K Clinton; Kenneth M Riedl; Yael Vodovotz; Steven J Schwartz
Journal:  Food Funct       Date:  2012-06-27       Impact factor: 5.396

3.  Prothrombotic markers in asymptomatic dyslipidemic subjects.

Authors:  David Karasek; Helena Vaverkova; Milan Halenka; Dagmar Jackuliakova; Zdenek Frysak; Ludek Slavik; Dalibor Novotny
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

4.  Clinical chemistry through Clinical Chemistry: a journal timeline.

Authors:  Robert Rej
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

5.  Correlation of metabolic syndrome severity with cardiovascular health markers in adolescents.

Authors:  Arthur M Lee; Matthew J Gurka; Mark D DeBoer
Journal:  Metabolism       Date:  2017-01-13       Impact factor: 8.694

6.  Lipids-risk categories in omani type 2 diabetics: impact of the national cholesterol educational program.

Authors:  Ali I Al-Bahrani; Riad Bayoumi; Said A Al-Yahyaee
Journal:  Sultan Qaboos Univ Med J       Date:  2006-12

Review 7.  Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.

Authors:  Allan Sniderman; Patrick Couture; Jacqueline de Graaf
Journal:  Nat Rev Endocrinol       Date:  2010-04-27       Impact factor: 43.330

8.  Reference distributions for apolipoproteins AI and B and B/AI ratios: comparison of a large cohort to the world's literature.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Thomas B Ledue; Santica Marcovina; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

9.  Association Between Apo Lipoprotein B Levels at Admission of Patients and Short-term Morbidity and Mortality After Myocardial Infarction.

Authors:  Sepideh Sokhanvar; Amirhossein Khoshi; Sanaz Hajiaghaei; S Nouraddin Mousavinasab; Zahra Golmohammadi
Journal:  J Cardiovasc Thorac Res       Date:  2012-09-23

10.  Reference intervals for serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, Lp (a), apolipoprotein A-I, A-II, B, C-II, C-III, and E in healthy South Indians from Andhra Pradesh.

Authors:  T Malati; M R U Mahesh
Journal:  Indian J Clin Biochem       Date:  2009-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.